| Objective:To compare the long-term efficacy of transcatheter arterialchemoembolization(TACE)combined with ablation and TACE alone in the treatment of recurrent hepatocellular carcinoma.Methods:By searching China National Knowledge Infrastructure(CNKI),Wanfang Database,China Science and Technology Journal Database(VIP),Cochrane Library,Pub Med,Embase database was used to collect literatures comparing TACE combined with ablation and TACE alone in the treatment of recurrent liver cancer from the establishment of the database to January 1,2022.The experimental group received TACE+ ablation,and the control group received TACE according to the inclusion and exclusion criteria,qualified literatures were screened out,relevant data and materials were extracted,and Rev Man was used 5.4 Meta-analysis was conducted to compare the effects of the two treatments on the overall survival rate(OS)and disease-free survival rate(DFS)of patients.Results:A total of 1363 patients were included in 6 articles,including 555 patients in the experimental group and 808 patients in the control group.Meta-analysis results show that:The overall survival rate(OS)at 1,3 and 5 years in experimental group was significantly better than that in control group(1-year OS: OR=1.91,95%CI: 1.47～2.48,P< 0.00001;3-year OS: OR=1.98,95%CI :1.57 ～ 2.49,P < 0.00001;5-year OS: OR=2.41,95% CI:1.86 ～ 3.13,P < 0.00001).The 1-,3-and 5-year disease-free survival rate(DFS)of experimental group was significantly better than that of control group(1-year DFS:OR=1.56,95%CI :1.09 ～ 2.22,P=0.01;3-year DFS: OR=2.20,95%CI :1.61 ～ 3.03,P <0.00001;5-year DFS: OR=2.04,95% CI:1.39 ～ 3.00,P=0.0003).Conclusion:TACE combined with ablation is a safe and effective treatment for recurrent liver cancer.As a first-line local treatment,TACE combined with ablation has better clinical efficacy than TACE alone,which can improve the overall survival and disease-free survival of patients and prolong the life of patients. |
PDF Full Text Request